This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Mylan Gets Abbott Generics Business in $5.3B Deal

Stocks in this article: MYL ABT

NEW YORK (The Deal) -- Mylan (MYL) said Monday it has a deal in place to acquire the developed markets generic drugs business of Abbott Laboratories (ABT) in a stock deal valued at $5.3 billion.

The assets to be acquired include a portfolio of more than 100 specialty and branded generic pharmaceutical products and several patent-protected products as well as an active sales organization of 2,000 representatives in more than 40 non-U.S. markets. The units generate about $1.9 billion in annual sales from operations in Europe, Japan, Canada, Australia and New Zealand.

Terms of the deal call for Abbott to receive 105 million Mylan shares, representing a 21% ownership stake in Mylan. Abbott in a statement said it does not expect to be a long-term shareholder in Mylan, saying that it plans to over time redeploy the proceeds from the deal.

Abbott chairman and CEO Miles D. White said that the sale provides his company "with additional strategic flexibility as we continue to actively manage and shape our portfolio, reflecting our commitment to long-term, durable growth."

Post-deal Mylan would be a $10 billion-sales entity with a portfolio of more than 1,400 specialty and generic products and a global infrastructure. As part of the deal the company will be organized in the Netherlands and be called Mylan NV, though it will be led by the current Mylan management team from their headquarters in Pittsburgh.

Mylan executive chairman Robert J. Coury said that the deal follows a look at "a wide range of opportunities," saying that the deal with Abbott is his company's best move.

The deal, he said, "expands and further diversifies our business in our largest markets outside of the U.S., and clearly positions Mylan for the next phase of growth through enhanced financial flexibility and a more competitive global tax structure."

Coury said that the purchase should "create significant additional cash financial flexibility" which Mylan intends to put to use "in this continually consolidating sector." Mylan's pro forma leverage at close is expected to be about 2.3 times adjusted Ebitda.

Mylan was advised by Alan Hartman and Ercement Tokat of Centerview Partners and a Cravath, Swaine & Moore LLP team including Mark Greene, Thomas Dunn, Scott Barshay, Stephen Gordon, J. Leonard Teti II and Eric Hilfers. Abbott sought financial advice from Morgan Stanley's Michael Boublick and legal counsel from Baker & McKenzie partners Olivia Tyrrell and Craig Roeder.

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 18,053.71 +23.50 0.13%
S&P 500 2,088.77 +6.89 0.33%
NASDAQ 4,806.8590 +33.3870 0.70%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs